TITLE

Review on Immunotherapies for Lung Cancer

AUTHOR(S)
Sha Jin; Jianhui Tian
PUB. DATE
October 2012
SOURCE
Chinese Journal of Lung Cancer;Oct2012, Vol. 15 Issue 10, p606
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Lung cancer is a highly malignant disease with poor prognosis, most cases are diagnosed at a very late stage. More effective medications or therapies should be developed to improve its prognosis. The advancement of tumor immunity and tumor immunosuppression facilitated the feasibility of immunotherapies for lung cancer. Ipilimumab, antibody to Programmed death-1 (PD-1), Toll-like receptor agonists, liposomal BLP25 (L- BLP25), belagenpumatucel-L, melanoma-associated antigen A3 (MAGE-A3) vaccine and talactoferrin have been proved to be effective for lung cancer through early clinical trials, most of the drugs have moved forward to phase III trials, so as to collect much higher level evidence to support the immunotherapies incorporated into the multidisciplinary treatment of lung cancer. The selection of target patients at appropriate stages, breaking down of tumor immunosuppression as well as the objective measurement of tumor response to the therapy are major challenges for the development of immunotherapies for lung cancer. The clarifying of the mechanism of immune escape led to the above drug development, and immune-senescence has already become the hotspot in this field.
ACCESSION #
82717006

 

Related Articles

  • The effect of subcutaneous tumour implantation in a murine lung tumour model. John, L.C.H. // European Journal of Cardio-Thoracic Surgery;Apr2002, Vol. 21 Issue 4, p616 

    Objectives: It was hypothesized that if tumour were implanted subcutaneously within a Millipore Chamber (MPC), then this would result in an ‘anti-tumour’ immune response. Such an approach could have potential as an adjuvant tumour therapy when combined with surgical resection. A...

  • Melanoma: More Answers, More Questions. URBA, WALTER S. // Oncologist;Jun2013, Vol. 18 Issue 6, p658 

    The article discusses recent advances in the treatment for metastatic melanoma. It cites a study by Luke and Hodi about the development of ipilinumab, an anti-CTLA-4 antibody that is presumed to enhance T-cell immunity. It also offers information on a recently developed immunotherapy to all...

  • Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma? Pirard, Grald E.; Aubin, Franois; Humbert, Philippe // Dermatology Research & Practice;2012, Vol. 2012, p1 

    Malignant melanoma (MM) is one of the most aggressive skin cancer. The therapeutic options remain limited for advanced MM, and those directed to the neoplastic cells have not brought major survival advantage so far. Immunotherapy is another targeted option. Ipilimumab, a monoclonal antibody...

  • Immunotherapy in the management of melanoma: current status. Alston, Dylan; Brewer, Jerry D. // ImmunoTargets & Therapy;2013, Vol. 2, p1 

    As the rate of melanoma continues to increase, so does the need for more effective and durable therapies. Despite considerable research, the management of advanced disease remains challenging. Numerous therapies are being investigated, many of which aim at upregulating the immune system's innate...

  • POINT/COUNTER. Sznol, Mario; Sullivan, Ryan J. // Hem/Onc Today;5/25/2014, Vol. 15 Issue 10, p11 

    The article presents insights on the use of immunotherapy as front-line therapy for all cancers, citing data from early clinical trials of agents blocking inhibitors of lymphocyte function, and the combination of ipilimumab in metastic carcinoma.

  • Eleventh international conference on progress in vaccination against cancer (PIVAC-11), 10-13 October 2011, Copenhagen, Denmark. Køllgaard, Tania; Berg, Joost; Donia, Marco; thor Straten, Per // Cancer Immunology, Immunotherapy;Aug2012, Vol. 61 Issue 8, p1349 

    No abstract available.

  • Serious haematological toxicity during and after ipilimumab treatment: a case series. Simeone, Ester; Grimaldi, Antonio Maria; Esposito, Assunta; Curvietto, Marcello; Palla, Marco; Paone, Miriam; Mozzillo, Nicola; Ascierto, Paolo Antonio // Journal of Medical Case Reports;2014, Vol. 8 Issue 1, p1 

    Introduction Immunotherapy with the anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab has been shown to improve overall survival in previously treated and treatmentnaïve patients with unresectable stage III or IV melanoma. Consistent with its proposed immunomodulating...

  • CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Callahan, Margaret K.; Postow, Michael A.; Wolchok, Jedd D. // Frontiers in Oncology;Jan2015, Vol. 5, p1 

    Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in...

  • A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. Uemura, Marc; Faisal, Faa'k; Haymaker, Cara; McQuail, Natalie; Sirmans, Elizabeth; Hudgens, Courtney W.; Barbara, Lydia; Bernatchez, Chantale; Curry, Jonathan L.; Hwu, Patrick; Tetzlaff, Michael T.; Diab, Adi // Journal for ImmunoTherapy of Cancer;9/20/2016, Vol. 4, p1 

    Background: Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover's disease is an uncommon dermatologic condition with unclear pathogenesis previously reported as an irAE with ipilimumab. Case Presentation:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics